바카라사이트 장난감2471 demonstrates safety and tolerability in single- and repeated- dose studies
[by Ji, Yong Jun] Vivozon announced on April 24 that the results of the Phase 1 clinical trial for ‘VVZ-2471 (development code)’, being developed as an oral treatment for pain and drug addiction, have been published in the latest issue of the international academic journal ‘CNS Drugs.’ The journal is a Science Citation Index Expanded (SCIE)-listed medical journal specializing in the central nervous system (CNS) field, with an impact factor (IF) of 7.4.
The published paper presents the results of single- and repeated-dose Phase 1 clinical trials of 바카라사이트 장난감2471, conducted at the Clinical Trial Center of Seoul National University Bundang Hospital. The study evaluated the following aspects: the safety and tolerability of orally administered 바카라사이트 장난감2471, its pharmacokinetic properties based on dosage, the impact of administration on food intake, and its effect on the desire to smoke.
As a result, 바카라사이트 장난감2471 demonstrated safety and tolerability even at high doses exceeding the anticipated therapeutic range, and dose-dependent pharmacodynamic properties were observed. Furthermore, an exploratory assessment of ‘smoking desire’ conducted on smokers confirmed a reduction in the urge to smoke, thereby supporting the potential as a treatment for addiction.
In June 2024, the company secured approval for a phase 2 clinical trial plan (IND) for the oral formulation of VVZ-2471 targeting patients with postherpetic neuralgia and is currently conducting the trial at three Korean institutions. The company aims to widely use the 바카라사이트 장난감 for pain management in the future along with ‘Unafra (opioid analgesic) injection,’ Korea’s 38th novel 바카라사이트 장난감 approved by the Ministry of Food and 바카라사이트 장난감 Safety in December of last year. Additionally, preparations are underway for Phase 2 clinical trials in the United States to develop the oral VVZ-2471 as a treatment for 바카라사이트 장난감 addiction in response to the country’s ongoing opioid misuse and addiction crisis.
VVZ-2471, Vivozon’s second pipeline, is a first-in-class 바카라사이트 장난감 candidate discovered through the company’s multi-target new 바카라사이트 장난감 development platform, similar to Opiranserin (VVZ-149). It exerts a dual antagonistic mechanism by simultaneously inhibiting ‘mGluR5’ and ‘5-HT2AR,’ two receptors that are associated with the transmission of addiction and pain signals.
“The publication of VVZ-2471’s clinical trial results in a prestigious international academic journal is significant, as it represents international recognition of the potential for developing an oral treatment for 바카라사이트 장난감 addiction,” a Vivozon official said. “We will continue to make every effort to improve patients’ ‘quality of life’ through the development of innovative new 바카라사이트 장난감s based on scientific evidence.”